Leerink Partners Issues Positive Forecast for PROCEPT BioRobotics (NASDAQ:PRCT) Stock Price

PROCEPT BioRobotics (NASDAQ:PRCT) had its price target boosted by Leerink Partners from $20.00 to $22.00 in a research note published on Thursday,Benzinga reports. The firm currently has a market perform rating on the stock.

A number of other equities analysts also recently commented on PRCT. Wells Fargo & Company downgraded PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 price objective on the stock. in a research report on Wednesday, August 5th. Evercore set a $23.00 price objective on PROCEPT BioRobotics in a research report on Wednesday, August 5th. Piper Sandler raised PROCEPT BioRobotics to a “strong-buy” rating in a research note on Friday, October 16th. William Blair downgraded PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Finally, TD Cowen dropped their price target on shares of PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, August 5th. Three equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $25.00.

PROCEPT BioRobotics Stock Performance

PRCT opened at $20.27 on Thursday. PROCEPT BioRobotics has a twelve month low of $16.67 and a twelve month high of $38.11. The company has a 50-day moving average price of $19.32 and a 200 day moving average price of $23.18. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.35 and a current ratio of 6.55.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.07). PROCEPT BioRobotics had a negative return on equity of 32.71% and a negative net margin of 32.60%. The firm had revenue of $98.29 million for the quarter, compared to analysts’ expectations of $100.52 million. During the same quarter last year, the firm posted ($0.38) earnings per share. PROCEPT BioRobotics’s quarterly revenue was up 18.0% on a year-over-year basis. Equities research analysts predict that PROCEPT BioRobotics will post -1.67 EPS for the current year.

Institutional Trading of PROCEPT BioRobotics

A number of large investors have recently modified their holdings of PRCT. Versant Capital Management Inc grew its position in shares of PROCEPT BioRobotics by 994.5% during the second quarter. Versant Capital Management Inc now owns 1,193 shares of the company’s stock worth $27,000 after buying an additional 1,084 shares in the last quarter. Nykredit A S acquired a new position in shares of PROCEPT BioRobotics during the second quarter worth $27,000. Sterling Capital Management LLC grew its stake in shares of PROCEPT BioRobotics by 849.2% during the third quarter. Sterling Capital Management LLC now owns 1,870 shares of the company’s stock worth $34,000 after purchasing an additional 1,673 shares in the last quarter. Signaturefd LLC raised its stake in PROCEPT BioRobotics by 162.7% in the third quarter. Signaturefd LLC now owns 1,899 shares of the company’s stock valued at $35,000 after buying an additional 1,176 shares in the last quarter. Finally, Essential Partners LLC boosted its position in shares of PROCEPT BioRobotics by 7,071.4% during the 1st quarter. Essential Partners LLC now owns 2,008 shares of the company’s stock worth $50,000 after acquiring an additional 1,980 shares in the last quarter. Hedge funds and other institutional investors own 89.46% of the company’s stock.

Trending Headlines about PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: UBS Group raised its price target from $20 to $21 and kept a neutral rating. UBS Group analyst ratings
• Positive Sentiment: Leerink Partners lifted its target from $20 to $22, maintaining a market-perform rating. The increases offer modest support, though neither analyst adopted a bullish rating. Leerink Partners analyst ratings
• Neutral Sentiment: The company reaffirmed its 2026 financial guidance, providing some reassurance but no upward revision to expectations. Third-quarter results and guidance
• Negative Sentiment: Q3 adjusted loss was $0.46 per share, wider than the $0.39 loss analysts expected and the $0.38 loss a year earlier. Revenue of $98.3 million also missed the $100.5 million consensus, despite growing 18% year over year. The earnings and revenue shortfalls likely weighed on the stock. Q3 results coverage

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation is a medical technology company focused on developing and commercializing robotic solutions for the treatment of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms. The company’s technology is designed to provide a minimally invasive alternative to conventional surgical procedures.

Its primary product is the AquaBeam Robotic System, which uses image guidance, robotic assistance and a high-velocity waterjet to remove targeted prostate tissue.